Fwd: [Two Advanced/Recurrent Breast Cancer Cases Effectively Treated by Trastuzumab/Capecitabine Combination Therapy.]

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Wed, Feb 20, 2008 at 4:02 AM
Subject: [Two Advanced/Recurrent Breast Cancer Cases Effectively Treated by Trastuzumab/Capecitabine Combination Therapy.]
To: mesothelioma77@gmail.com


[1]Gan To Kagaku Ryoho. 2008 Feb; 35(2): 319-322
Inoue S, Inoue M, Takahashi H, Inoue A, Kunitomo K, Fujii H

Trastuzumab/capecitabine combination therapy was performed for two advanced/recurrent breast cancer cases with acute deterioration of the disease. The time until partial response in the first case was 7 months and in the second case 12 months. Adverse events were slight, though a standard dose as a single drug was used for each drug. The treatment time course was shortened because capecitabine was an oral drug. Therefore, this combination therapy was expected to maintain high quality of life and obtain a high response rate.



___
Source: http://www.hubmed.org/display.cgi?uids=18281774
--
 

Fwd: [A 23-Year Delayed Locoregional Recurrence of Breast Carcinoma Following Mastectomy.]

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Wed, Feb 20, 2008 at 4:02 AM
Subject: [A 23-Year Delayed Locoregional Recurrence of Breast Carcinoma Following Mastectomy.]
To: mesothelioma77@gmail.com


[1]Gan To Kagaku Ryoho. 2008 Feb; 35(2): 323-326
Ogo E, Etou H, Suzuki G, Suefuji H, Tsuji C, Hattori C, Hayabuchi N

A 77-year-old woman who underwent a right modified radical mastectomy 23 years ago with no further adjuvant treatment presented with a right chest wall mass (3x4x2 cm) at the scar. She had no symptoms nor metastasis. The laboratory data were normal including tumor marker. The mass was diagnosed as compatible with a local recurrence tumor from the previous breast cancer on the ultrasonography and chest CT. After obtaining her informed consent for the therapy, we performed 60 Gy/30 fr radiotherapy on the recurrent tumor on her right chest wall with concurrent oral chemo-endocrine therapy. The first regimens were tamoxifen 20 mg/day and 5'-DFUR 600 mg/day, followed by tore- mifene 80 mg/day and 5'-DFUR 600 mg/day, and then the tumor disappeared. But three years later, we found tumor regrowth. We changed the regimen, giving 5'-DFUR 1,200 mg/day and cyclophosphamide 100 mg/day for 2 weeks followed by a 1-week drug-free period, then added 10 Gy/5 fr radiotherapy and hyperthermia twice a week. Final regimens were anastrozole 1 mg/day and capecitabine 900 mg/day. The recurrent tumor decreased and the disease stabilized. After these therapies, she had very good quality of life. We recommend radiation and/or hyperthermia with concurrent oral chemo-endocrine therapy as useful for the delayed recurrence of elderly breast cancer after a modified radical mastectomy.



___
Source: http://www.hubmed.org/display.cgi?uids=18281775
--
To unsubscribe from [2]this feed, click [3]here
To manage other subscriptions, click [4]here
~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc